FIGURE 1


2286
2287
2290
2289
2294
2324
absorbance 490 nm
1.5
1.0
0.5
0.0
Calbio 1-42
Calbio 1-40
Bachem 1-43
β-APP (gD)
(-) ctrl peptide
Assay Format: peptide + Ab + GAMIgG(Fc)HRP

FIGURE 2


2286
2287
2290
2289
2294
2324
mo anti-ßAPP
6E10
absorbance 490 nm
2.0
1.5
1.0
0.5
0.0
Maximum Binding
(no soluble A-ß)
Preincubation with
10 µg/ml A-ß
Assay Format: A-ß + MAb [± soluble A-ß] + GAMIgG(Fc)-HRP

FIGURE 3


MAb 2286
MAb 2289
MAb 2324
% of Maximal Binding
0
20
40
60
80
100
None
1-16
1-28
1-38
1-40
1-42
1-43
42-1
β Amyloid Peptide Fragment

FIGURE 4


A-beta total hippocampus
A-beta total frontal cortex
Thioflavine-S Hippocampus
Thioflavine-S Frontal Cortex
MHC-II hippocampus
MHC-II frontal cortex
Ratio right:left side
Antibody
vehicle
2286
2324
2289
Anti-amnesiac

FIGURE 5



FIGURE 6


A
B
C
CD45 ratio right:left sides
Aβ ratio right:left sides
thio-S ratio right:left sides
P<0.001
P<0.01
P<0.02
***
**
*
IgG-Cont
F(ab')2-Cont
IgG-Abeta
F(ab')2-Abeta
0
10
20
30
1
2
3

FIGURE 7


125
100
75
50
25
0
Aβ [nM]
500
400
300
200
100
0
Anti-Aβ Antibodies [nM]
Injected agent:
Vehicle
2286
Control IgG1
2286
2286
2286
Duration [Months]:
3
3
3
1
2
3
Genotype:
WT
Tg2576

FIGURE 8


2286
2324
OD450
3
2.5
2
1.5
1
0.5
0
1-40 wt
1-41 wt
V40A (1-40)
V39A (1-40)
G38A (1-40)
G37A (1-40)
V36A (1-40)
Aβ variant